Big news! My K99 application has been awarded 🥳🎉
I'm excited to work together with @zenbrainest.bsky.social and @MarkZylka to explore how distinct peripheral neuron types shape pain representation in the brain.
I'm excited to work together with @zenbrainest.bsky.social and @MarkZylka to explore how distinct peripheral neuron types shape pain representation in the brain.
August 8, 2025 at 4:51 PM
Big news! My K99 application has been awarded 🥳🎉
I'm excited to work together with @zenbrainest.bsky.social and @MarkZylka to explore how distinct peripheral neuron types shape pain representation in the brain.
I'm excited to work together with @zenbrainest.bsky.social and @MarkZylka to explore how distinct peripheral neuron types shape pain representation in the brain.
🌟 Excited to share our new review published in RAPM ! 🌟
Happy to have worked with Cyril Rivat and Philippe Richebé on this piece of work in which we explore the mechanisms underlying chronic post-surgical pain.
rapm.bmj.com/content/50/2...
Happy to have worked with Cyril Rivat and Philippe Richebé on this piece of work in which we explore the mechanisms underlying chronic post-surgical pain.
rapm.bmj.com/content/50/2...
Mechanisms of chronic postsurgical pain
Chronic pain after surgery, also known as chronic postsurgical pain (CPSP), is recognized as a significant public health issue with serious medical and economic consequences. Current research on CPSP ...
rapm.bmj.com
February 9, 2025 at 2:21 PM
🌟 Excited to share our new review published in RAPM ! 🌟
Happy to have worked with Cyril Rivat and Philippe Richebé on this piece of work in which we explore the mechanisms underlying chronic post-surgical pain.
rapm.bmj.com/content/50/2...
Happy to have worked with Cyril Rivat and Philippe Richebé on this piece of work in which we explore the mechanisms underlying chronic post-surgical pain.
rapm.bmj.com/content/50/2...
Reposted by Adrien Tassou
A big day for pain care, and for pain science. www.fda.gov/news-events/...
FDA Approves Novel Non-Opioid Treatment for Moderate to Severe Acute Pain
The FDA approved Journavx (suzetrigine) 50 mg oral tablets, a first-in-class non-opioid analgesic to treat moderate to severe acute pain in adults.
www.fda.gov
January 30, 2025 at 11:36 PM
A big day for pain care, and for pain science. www.fda.gov/news-events/...
Reposted by Adrien Tassou
I am glad to share our recent work, now published in Cell! A @zenbrainest.bsky.social and Scherrer lab collaboration developing and validating a new peripherally restricted DREADD system! Great team work with Hye Jin Kang, Brian Krumm, @adrtas.bsky.social, and others
www.cell.com/cell/abstrac...
www.cell.com/cell/abstrac...
Structure-guided design of a peripherally restricted chemogenetic system
Kang et al. present HCAD, a peripherally restricted DREADD based on HCA2, with a chemical actuator that avoids crossing the blood-brain barrier and selectively reduces pain in mice. This system will enable the study of peripheral physiology without affecting the central nervous system.
www.cell.com
December 7, 2024 at 1:41 AM
I am glad to share our recent work, now published in Cell! A @zenbrainest.bsky.social and Scherrer lab collaboration developing and validating a new peripherally restricted DREADD system! Great team work with Hye Jin Kang, Brian Krumm, @adrtas.bsky.social, and others
www.cell.com/cell/abstrac...
www.cell.com/cell/abstrac...